| Previous Close | 0.515 |
| Open | 0.522 |
| Bid | 0.000 x 800 |
| Ask | 0.000 x 2200 |
| Day's Range | 0.493 - 0.580 |
| 52 Week Range | 0.350 - 4.950 |
| Volume | 2,910,499 |
| Avg. Volume | 2,367,341 |
| Market Cap | 57.746M |
| Beta | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.265 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.00 |
Pomerantz LLP announces that a class action lawsuit has been filed against Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (AMPE) and certain of its officers. The class action, filed in United States District Court, District of Colorado, and index under 18-cv-02252, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired the publicly traded securities of Ampio between December 14, 2017 and August 7, 2018, both dates inclusive (the “Class Period”). Plaintiff seeks to recover compensable damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder.
NEW YORK, Sept. 21, 2018-- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving ...
NEW YORK, NY / ACCESSWIRE / September 21, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Ampio Pharmaceuticals, Inc. (NYSE: ...
Law Offices of Howard G. Smith reminds investors of the October 24, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE) securities between December 14, 2017 and August 7, 2018, inclusive (the “Class Period”). Investors suffering losses on their Ampio investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
NEW YORK, Sept. 20, 2018-- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (AMPE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Ampio securities between December 14, 2017 through August 7, 2018, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/ampe. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
NEW YORK, NY / ACCESSWIRE / September 19, 2018 / Pomerantz LLP announces that a class action lawsuit has been filedagainst Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (AMPE) and certain of its officers. The class action, filed in United States District Court, District of Colorado, and index under 18-cv-02252, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired the publicly traded securities of Ampio between December 14, 2017 and August 7, 2018, both dates inclusive (the "Class Period"). Plaintiff seeks to recover compensable damages caused by Defendants'violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder.
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between December 14, 2017 and August 7, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before October 24, 2018. We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge.
Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired securities of Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE) between December 14, 2017, and August 7, 2018, inclusive (the “Class Period”). Ampio investors have until October 24, 2018, to file a lead plaintiff motion. On August 7, 2018, Ampio disclosed that the U.S. Food and Drug Administration (“FDA”) notified the Company that the FDA does not consider the Company’s AP-003-C trial to be an adequate and well-controlled clinical trial, and that the Company’s AP-003-A study, alone, does not appear to provide sufficient evidence of effectiveness to support a biologics license application.
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between December 14, 2017 and August 7, 2018, inclusive (the "Class Period"), are encouraged to contact the firm before October 24, 2018. We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge.
NEW YORK, Sept. 18, 2018-- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE) securities between December 14, 2017 and August 7, 2018, inclusive (the “Class Period”). Ampio investors have until October 24, 2018, to file a lead plaintiff motion. Investors that suffered losses on their Ampio investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
NEW YORK, Sept. 17, 2018-- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving ...
NEW YORK, Sept. 17, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) and certain of its officers. The class action, filed in United States District Court, District of Colorado, and index under 18-cv-02252, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired the publicly traded securities of Ampio between December 14, 2017 and August 7, 2018, both dates inclusive (the "Class Period"). Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder.
NEW YORK, Sept. 16, 2018-- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...
If you are a shareholder who purchased Ampio securities between December 14, 2017, and August 7, 2018, both dates inclusive, you have until October 24, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK, Sept. 14, 2018-- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...
NEW YORK, NY / ACCESSWIRE / September 14, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ampio Pharmaceuticals, Inc. ("Ampio" or ...
NEW YORK, Sept. 13, 2018-- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving ...
Dr. David Bar-Or, a member of Ampio's Scientific Advisory Board (SAB) and senior author, explains "This paper provides preliminary evidence that Ampion™ may trigger and support new cartilage growth in joints affected by Osteoarthritis (OA). As OA develops, the cells that make up cartilage, chondrocytes, begin to malfunction, contributing to cartilage breakdown. If the malfunctioning chondrocytes re-started normal function, the breakdown of existing cartilage would cease, and new cartilage may form, contributing to increased joint function".
NEW YORK, NY / ACCESSWIRE / September 12, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (AMPE) and certain of its officers. The class action, filed in United States District Court, District of Colorado, and index under 18-cv-02252, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired the publicly traded securities of Ampio between December 14, 2017 and August 7, 2018, both dates inclusive (the "Class Period"). Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder.
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Ampio Pharmaceuticals, Inc. (AMPE) have filed a shareholder derivative complaint against the company's officers and directors for breaches of fiduciary duties beginning December 14, 2017 and continuing through the present. Ampio develops compounds that decrease inflammation.
NEW YORK , Sept. 12, 2018 /PRNewswire/ -- Ampio Pharmaceuticals (AMPE) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the effectiveness and adequacy ...
NEW YORK, Sept. 12, 2018-- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...
NEW YORK, NY / ACCESSWIRE / September 12, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Ampio Pharmaceuticals, Inc. (NYSE: ...